Page 2 - நாள்பட்ட கல்லீரல் தோல்வி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நாள்பட்ட கல்லீரல் தோல்வி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நாள்பட்ட கல்லீரல் தோல்வி Today - Breaking & Trending Today

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis


Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis
Promising data supports advancing VS-01 into Phase 2a POC study in Acute on Chronic Liver Failure
Versantis, a clinical-stage company developing novel therapies for orphan liver and pediatric diseases, today announced positive results from a Phase 1b clinical trial of VS-01 in decompensated liver cirrhosis. VS-01 was found to be safe and well tolerated in this first-in-human, single ascending and multiple dose study led by Prof. Dr. Jonel Trebicka at the Goethe University Hospital Frankfurt. VS-01 is a potentially lifesaving, multi-organ support therapy that aims to reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins from the body. ....

Kostenloser Wertpapierhandel , Meriam Kabbaj , Vincent Foster , Jonel Trebicka , Vincent Forster , Lorenz Pabijan , Mike Sinclair , Goethe University Hospital Frankfurt , Chronic Liver Failure , Goethe University Hospital , Acute On Chronic Liver Failure , Prof Trebicka , Mrs Graf Dirmeier , Mrs Lorenz Pabijan , Rare Pediatric Diseases Designation , வின்சென்ட் வளர்ப்பு , வின்சென்ட் ஃபார்ஸ்டர் , மைக் சின்க்ளேர் , கோதீ பல்கலைக்கழகம் மருத்துவமனை பிராங்க்ஃபர்ட் , நாள்பட்ட கல்லீரல் தோல்வி , கோதீ பல்கலைக்கழகம் மருத்துவமனை , எடுப்போசை ஆன் நாள்பட்ட கல்லீரல் தோல்வி , ரேர் குழந்தை நோய்கள் பதவி ,

Albumin provides no benefit to hospitalized patients with advanced liver disease


 E-Mail
Daily infusions of albumin provide no significant health benefit to patients hospitalised with advanced liver disease, over and above standard care , finds a large-scale multicentre trial led by UCL researchers.
Albumin is a protein made in the liver that prevents fluid leaking from the bloodstream to other body tissues and carries various substances throughout the body, such as hormones or enzymes. In people with liver disease, low albumin levels are associated with an increased risk of death among hospitalised patients who have cirrhosis, and laboratory studies have shown albumin to have an anti-inflammatory effect. Therefore, albumin infusions are considered the best fluid for patients with cirrhosis and are an integral part of clinical care. ....

United Kingdom , City Of , Glasgow City , Digestive Health , Institute For Liver , University Of Nottingham , London School Of Medicine , University Of Glasgow , Thurrock University Hospitals , Division Of Medicine , Queen Mary University Of London , Department Of Health , Health Innovation Challenge Fund , Principal Investigator , Professor Alastairo Brien , New England Journal , Clinical Director , Clinical Trials Unit , London School , Queen Mary University , Glasgow Royal Infirmary , National Institute , Nottingham University Hospitals , South Essex , Bristol Royal , Social Care ,